ATyr Pharma Announces Publication Demonstrating Efficacy Of Efzofitimod In Pulmonary Sarcoidosis In The European Respiratory Journal
ATyr Pharma Announces Publication Demonstrating Efficacy Of Efzofitimod In Pulmonary Sarcoidosis In The European Respiratory Journal
Post hoc analysis of Phase 1b/2a study demonstrated statistically significant difference in time-to-first-relapse for corticosteroid use in therapeutic (3.0 and 5.0 mg/kg efzofitimod) vs subtherapeutic (1.0 mg/kg efzofitimod and placebo) groups.
在第1b/2a期研究的事後分析中，糖皮質激素治療組（3.0和5.0 mg/kg efzofitimod）與亞治療組（1.0 mg/kg efzofitimod和安慰劑）在首次復發時間上顯示出顯著差異。
54.4% of patients in the subtherapeutic group relapsed following corticosteroid taper, compared to 7.7% in the therapeutic group.
亞治療組中有54.4%的患者在糖皮質激素減量後出現復發，而治療組爲7.7%。
SAN DIEGO, Oct. 02, 2024 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (NASDAQ:ATYR) ("aTyr" or the "Company"), a clinical stage biotechnology company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced the publication of a post hoc analysis of the Phase 1b/2a clinical trial of its lead therapeutic candidate, efzofitimod, in patients with pulmonary sarcoidosis, a major form of interstitial lung disease, in the European Respiratory Journal. The publication, entitled, "Therapeutic Doses of Efzofitimod Demonstrate Efficacy in Pulmonary Sarcoidosis," is available on the Journal's website and at: .
2024年10月2日，聖地亞哥（SAN DIEGO），aTyr Pharma, Inc.（納斯達克:ATYR）（"aTyr"或"公司"），一家從其專有tRNA合成酶平台發現和開發首創藥物的臨床階段生物技術公司，今天宣佈其主力治療候選藥Efzofitimod在肺結節病患者中的1b/2a期臨床試驗的事後分析結果在《歐洲呼吸雜誌》上發表。該出版物名爲"Efzofitimod治療劑量在肺結節病中顯示療效"，可在該雜誌的網站和網址上獲取。
譯文內容由第三人軟體翻譯。